Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal misoprostol plus oxytocin versus oxytocin alone for prevention of postpartum haemorrhage
PACTR202512770937526Phase 1Not yet recruiting
- Sponsor
- Nwosa Amechi Augustine
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of misoprostol and oxytocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Nwosa Amechi Augustine. Primary endpoint: Postpartum blood loss of at least 500 mL. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
misoprostoloxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202512770937526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202512770937526.